Literature DB >> 10595745

A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells.

G Nishimura1, S Yanoma, H Mizuno, K Kawakami, M Tsukuda.   

Abstract

The anti-tumor effect of a selective cyclooxygenase (COX)-2 inhibitor, JTE-522, was examined with the human head and neck squamous cell carcinoma cell line KB. KB cells do not produce prostaglandin (PG)-E2. In vitro, JTE-522 induced an increase of G1 phase-arrested cells, suppression of platelet-derived growth factor (PDGF) production and inhibition of telomerase activity. No cytotoxic effect was detected. In vivo, the growth of the tumor xenografted into nude mice was significantly suppressed by JTE-522. Suppression of angiogenesis at the periphery of the tumor, increase of G1-arrested cells and suppression of telomerase activity were observed, together with an increase of apoptotic cell death in the tumor. Immunological enhancement did not play a role. We concluded that the anti-tumor effect of JTE-522 was caused by anti-angiogenesis action, cell cycle arrest and inhibition of telomerase activity of the tumor cells. These combined effects might induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595745      PMCID: PMC5925997          DOI: 10.1111/j.1349-7006.1999.tb00690.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  41 in total

1.  Propagation in a fluid medium of a human epidermoid carcinoma, strain KB.

Authors:  H EAGLE
Journal:  Proc Soc Exp Biol Med       Date:  1955-07

Review 2.  Aspirin use and potential mechanisms for colorectal cancer prevention.

Authors:  C S Williams; W Smalley; R N DuBois
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 3.  Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer.

Authors:  G N Levy
Journal:  FASEB J       Date:  1997-03       Impact factor: 5.191

4.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Authors:  T Kawamori; C V Rao; K Seibert; B S Reddy
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

5.  Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats.

Authors:  M Matsushita; M Masaki; Y Yagi; T Tanaka; K Wakitani
Journal:  Inflamm Res       Date:  1997-11       Impact factor: 4.575

Review 6.  Prostaglandins, their inhibitors and cancer.

Authors:  A Lupulescu
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1996-02       Impact factor: 4.006

7.  Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.

Authors:  K Müller-Decker; K Scholz; F Marks; G Fürstenberger
Journal:  Mol Carcinog       Date:  1995-01       Impact factor: 4.784

8.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

Review 9.  Eicosanoids and the gastrointestinal tract.

Authors:  C E Eberhart; R N Dubois
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.

Authors:  R N DuBois; A Radhika; B S Reddy; A J Entingh
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  14 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.

Authors:  Yara Peluso Cid; Vinícius Pedrazzi; Valéria Pereira de Sousa; Maria Bernadete Riemma Pierre
Journal:  AAPS PharmSciTech       Date:  2011-12-09       Impact factor: 3.246

Review 3.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

Review 4.  Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.

Authors:  Robert Vander Broek; Grace E Snow; Zhong Chen; Carter Van Waes
Journal:  Oral Oncol       Date:  2013-10-28       Impact factor: 5.337

Review 5.  Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.

Authors:  Josephine Chou; Yu-Ching Lin; Jae Kim; Liang You; Zhidong Xu; Biao He; David M Jablons
Journal:  Head Neck       Date:  2008-07       Impact factor: 3.147

6.  Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.

Authors:  Hiroyuki Konno; Megumi Baba; Tuyoshi Shoji; Manabu Ohta; Shohati Suzuki; Satoshi Nakamura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Host cyclooxygenase-2 modulates carcinoma growth.

Authors:  C S Williams; M Tsujii; J Reese; S K Dey; R N DuBois
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

8.  Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.

Authors:  Jun Yu; Bao-Dong Tang; Wai-K Leung; Ka-Fai To; Alfa-Hc Bai; Zhi-Rong Zeng; Po-Ki Ma; Minnie-Yy Go; Pin-Jin Hu; Joseph-Jy Sung
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

9.  Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.

Authors:  Pamela Zengel; Diana Ramp; Brigitte Mack; Stefan Zahler; Alexander Berghaus; Bernd Muehlenweg; Olivier Gires; Suna Schmitz
Journal:  BMC Cancer       Date:  2010-03-11       Impact factor: 4.430

10.  Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line.

Authors:  Yu Baoping; Hu Guoyong; Yu Jieping; Ran Zongxue; Luo Hesheng
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.